Organic Active Ingredients TRIZ Cases

Novel brominated resorcinol derivatives deliver anticonvulsant activity across seizure types while supporting flexible oral, transdermal, and parenteral dosing.

Crystalline trilaciclib citrate improves stability, handling, and dissolution while managing formulation complexity for cancer drug development.

Targeting LAT1 with Nanvuranlat addresses chemotherapy-refractory biliary tract cancer in high-LAT1, Non-Rapid NAT2 patients.

Raising brain NADPH via ME1, IDH1, or G6PD shifts mitochondrial disease treatment beyond ATP replacement and suppresses neuroinflammation.

Novel spiro and fused polycyclic compounds stabilize microtubules to target glioma cells while limiting neuronal harm.

Defined crystal and salt forms of compound A improve stability and bioavailability, supporting development of anti-tumor drugs.

Acid addition salts of this antidepressant improve solubility and stability, supporting formulation while helping reduce gastrointestinal side effects.

Cross-linked hyaluronic acid microgels extend intraocular anti-VEGF release beyond 30 days, reducing repeat injections and patient burden.

A membrane-permeable anti-HER2 ADC extends treatment to low-expression breast cancer through bystander killing with lower pneumonia risk.

Stable Form I and Form VI kinase inhibitor crystals preserve polymorphic integrity and pharmacokinetic consistency for cancer treatment.

Buffering selatogrel solution to pH 8.2 or above prevents storage degradation while preserving rapid subcutaneous platelet inhibition.

New quinazoline crystalline forms improve blood-brain barrier penetration and ErbB2 selectivity for treating breast cancer brain metastases.

Defined 40-130 mg/day oral dosing over at least 25 days improves MDD treatment reliability while balancing efficacy and adverse effects.

A ciclopirox composition with tocopherol and alginate reduces gastrointestinal toxicity while maintaining oral bioavailability and efficacy.

A multi-herb influenza formulation uses standardized soaking, decoction, and concentration steps to improve antiviral consistency and immune support.

Using sitagliptin maleate and non-hygroscopic excipients, this case improves tablet stability, solubility, and bioavailability.

Targeting RIPK1 with eclitasertib reduces inflammation and restores skin architecture in lichen planus and cutaneous lupus.

Citric acid forms a sublingual epinephrine reservoir for rapid uptake and sustained plasma levels when low blood pressure limits injection absorption.

A quinazoline derivative targets EGFR C797S-related resistance to osimertinib, helping treat NSCLC and CNS metastases.

Two-step supercritical CO2 extraction, adsorption, and crystallization separate kavalactone from flavokawains to improve purity and safety.

Novel GPR17-modulating compounds drive oligodendrocyte maturation to enhance myelination and remyelination in CNS demyelinating disorders.

Minimally processed amnion-chorion tissue with an intact spongy layer preserves endogenous growth factors for improved wound healing.

Substituted aryl and heteroaryl amides inhibit HIF-1α prolyl hydroxylase to boost angiogenesis, erythropoietin, and oxygen delivery.

Targeting Ugt2b1 with an siRNA duplex lowers UGT and blood glucose, offering a less invasive diabetes treatment approach.

A desiccant chamber and air-permeable membrane balance luminaire pressure while limiting moisture ingress and condensation outdoors.

Deleting the CDR-H2 glycosylation site in an anti-MUC1 ADC boosts tumor-cell binding and improves efficacy against MUC1-positive tumors.

Aptamer-based detection improves irinotecan monitoring by reducing SN-38 cross-reactivity and background signal in clinical samples.

Dialysis loads organic compounds into hydrogels at target concentration, achieving uniform distribution without homogenization or hydrogel degradation.

Cinnamic acid is metabolized to benzoate in the liver, sustaining therapeutic levels with less frequent dosing and fewer side effects.

Thyroid hormones such as Triac, T3, and T4 up-regulate zeta-globin expression, offering a safer, lower-cost option than transfusion-based alpha-thalassemia care.

Deuterium substitution slows domperidone metabolism, extends drug retention, and supports lower dosing with fewer cardiac side effects.

Removing endotoxin, propylene glycol, and undefined cyclodextrin species enables safer chronic CNS dosing for Niemann-Pick C.

Targeting ligands linked by click chemistry improve nucleic acid delivery, in vivo stability, and dosing efficiency while limiting toxicity.

Oral amine polymers bind uric acid in the gut to lower serum levels and treat gout or hyperuricemia with fewer side effects.

Selective disulfide rebridging linkers create homogeneous high-DAR antibody conjugates with better stability, half-life, and lower off-target toxicity.

Targeting splice donor and acceptor sites in T-antigen pre-mRNA suppresses polyomavirus replication and lowers virus production.

Formula I reversible DPP1 inhibitor compounds reduce neutrophil elastase-driven inflammation and tissue damage in inflammatory disease treatment.

Restricting multiple non-essential amino acids selectively starves cancer cells, boosts treatment response, and supports biomarker-guided patient selection.

CD5-targeted TCR therapy uses HLA-A*02-restricted recognition and HLA/CD5 suppression strategies to limit T-cell fratricide in lymphoma treatment.

Novel pyrimidine KHK inhibitors balance strong fructose-metabolism blockade with oral bioavailability for daily treatment of metabolic disorders.

An alginate filler stays injectable, then partially crosslinks in situ to restore nucleus pulposus strength and support disc regeneration.

Flexible inner and rigid outer flaps self-size around vessels to maintain electrode contact, improve coverage, and limit nerve compression.

A segmented chemical route uses Grignard and oxidation steps to raise Lemborexant yield while minimizing process impurities.

LCC18 targets renal fibrosis progression by reducing glomerular proliferation, sclerosis, and immune responses while improving renal function.

Modular Formula (I) EZH2 inhibitor scaffolds improve selectivity and activity while easing synthesis for broad cancer treatment.

Low-nanomolar 2-arylvinylquinolines target chloroquine-resistant P. falciparum with fast blood-stage action and transmission-blocking potential.

Short-course platinum doublet induction before anti-PD-1 and anti-CTLA-4 therapy improves NSCLC response while limiting chemotherapy exposure.

ATP-binding lipid switches reshape liposome membranes to trigger selective drug release in diseased cells while limiting harm to healthy tissue.

Scheduled serum urate checks and threshold-based intervention help maintain milsaperidone therapy while limiting hyperuricemia and gout risk.

Specific post-meal intervals for oral edaravone reduce absorption variability and maintain fasting-like pharmacokinetics across meal types.